Using duloxetine to prevent nerve damage from chemotherapy in cancer patients
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
This study is looking at whether the medication duloxetine can help prevent numbness and tingling in the hands and feet caused by oxaliplatin treatment in people with colorectal cancer, and it will involve patients from different locations to see how well it works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10756924 on NIH RePORTER |
What this research studies
This research investigates whether duloxetine can prevent oxaliplatin-induced peripheral neuropathy (OIPN) in patients undergoing treatment for colorectal cancer. OIPN is a common side effect characterized by numbness and tingling in the extremities, which can lead to pain and significantly impact quality of life. The study will involve a randomized, double-blind, placebo-controlled design, where participants will receive either duloxetine or a placebo to assess its effectiveness in preventing these symptoms. The research will be conducted across multiple sites, allowing for a diverse patient population to participate.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with stage II-IV colorectal cancer who are scheduled to receive oxaliplatin as part of their treatment.
Not a fit: Patients who are not receiving oxaliplatin or those with contraindications to duloxetine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a preventive treatment option for patients at risk of developing painful nerve damage from chemotherapy.
How similar studies have performed: Previous studies have shown promising results for duloxetine in treating established OIPN, indicating potential for its preventive use.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Smith, Ellen Mary Lavoie — University of Alabama at Birmingham
- Study coordinator: Smith, Ellen Mary Lavoie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.